SEDAR Interim Financial Statements

[
  {
    "companyName": "DiagnaMed Holdings Corp.",
    "reportingPeriodEnd": "2025-12-31",
    "reportStatus": "Unaudited",
    "auditorName": null,
    "auditorKeyMatters": [],
    "balanceSheet": {
      "cashAndCashEquivalents": 128406,
      "amountsReceivable": 24247,
      "prepaidExpenses": 14656,
      "totalCurrentAssets": 167309,
      "totalAssets": 167309,
      "tradeAndOtherPayables": 439955,
      "totalCurrentLiabilities": 439955,
      "totalLiabilities": 439955,
      "commonShares": 4532249,
      "contributedSurplus": 1543894,
      "deficit": -6348789,
      "totalShareholdersDeficiency": -272646,
      "totalLiabilitiesAndShareholdersDeficiency": 167309,
      "cashPerShare": 0.0011,
      "workingCapitalPerShare": -0.0024
    },
    "incomeStatement": {
      "consultingFees": 41093,
      "generalAndAdministrative": 4789,
      "investorRelations": 42782,
      "professionalFees": 3000,
      "researchAndDevelopment": null,
      "shareBasedPayments": 8450,
      "lossGainOnForeignExchange": -13060,
      "lossAndComprehensiveLossBeforeBelowItems": -87054,
      "interestIncome": 652,
      "netLossAndComprehensiveLossForThePeriod": -86402,
      "weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 113759426,
      "basicAndDilutedLossPerCommonShare": -0.0008
    },
    "cashFlowStatement": {
      "netLossForThePeriod": -86402,
      "shareBasedPayments": 8450,
      "gainOnSettlementOfDebt": null,
      "changesInAmountsReceivable": -6650,
      "changesInPrepaidExpenses": 276,
      "changesInTradeAndOtherPayables": -226517,
      "netCashUsedInOperatingActivities": -310843,
      "proceedsFromTheExerciseOfWarrants": 255417,
      "netCashProvidedByFinancingActivity": 255417,
      "changeInCashDuringThePeriod": -55426,
      "cashAndCashEquivalentsBeginningOfThePeriod": 183832,
      "cashAndCashEquivalentsEndOfThePeriod": 128406
    },
    "investmentsAndOtherAssets": [
      {
        "type": "Mineral/Resource Properties",
        "description": "Acquisition of 91 unpatented, single-cell mineral claims (1,820 hectares) in Ontario's Temiscamingue hydrogen district",
        "ownershipPercentage": null,
        "value": null,
        "notes": "Paid with 12,500,000 common shares and $25,000 non-refundable payment. Granted sellers a 2.0% royalty on revenues; 50% purchasable for $2 million."
      },
      {
        "type": "Mineral/Resource Properties",
        "description": "Colchester East Natural Hydrogen Project in Nova Scotia (30 licenses, 2,104 claims)",
        "ownershipPercentage": null,
        "value": null,
        "notes": "Acquisition agreement signed Dec 5, 2025. Purchase price: $10,000 + 10,000,000 common shares. Sellers retain 2% revenue royalty, half repurchasable for $2 million. Subject to regulatory approval."
      }
    ],
    "shareStructure": {
      "authorizedShares": "Unlimited",
      "issuedShares": 114267306,
      "classesOfShares": ["Common shares"],
      "warrants": [
        {
          "number": 9134027,
          "exercisePrice": 0.05,
          "expiryDate": "2027-04-11"
        }
      ],
      "options": [
        {
          "number": 200000,
          "exercisePrice": 0.10,
          "expiryDate": "2027-01-04"
        },
        {
          "number": 2475000,
          "exercisePrice": 0.05,
          "expiryDate": "2028-07-17"
        },
        {
          "number": 3000000,
          "exercisePrice": 0.05,
          "expiryDate": "2029-11-11"
        }
      ],
      "rightsConvertibleInstruments": null
    },
    "managementCompensation": {
      "currency": "CAD",
      "periods": {
        "2025": {
          "managementFees": 29546,
          "consultingFees": 11547,
          "shareBasedPayments": 8450,
          "total": 49543
        },
        "2024": {
          "managementFees": 14292,
          "consultingFees": null,
          "shareBasedPayments": 23171,
          "total": 37463
        }
      },
      "namedIndividuals": [],
      "otherRelatedPartyTransactions": []
    },
    "subsequentEvents": [
      {
        "eventDate": "2026-02-23",
        "description": "Financial statements approved and authorized for issuance by the Board of Directors.",
        "impactValue": null
      }
    ]
  }
]